Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | TSPO | P30536 | 1/20 | 0.31 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20175565 | 1.00 | KDM4E (0.37) | KDM4EATML3MBTL1ALOX5MAPT | |
| SCHEMBL20175559 | 0.99 | KDM4E (0.36) | KDM4EATML3MBTL1ALOX5MAPT | |
| SCHEMBL20175566 | 0.99 | KDM4E (0.36) | KDM4EATML3MBTL1ALOX5MAPT | |
| SCHEMBL20175563 | 0.99 | KDM4E (0.35) | KDM4EATML3MBTL1ALOX5MAPT | |
| SCHEMBL20175672 | 0.97 | L3MBTL1 (0.39) | KDM4EATML3MBTL1ALOX5MAPT | |
| SCHEMBL20175674 | 0.97 | L3MBTL1 (0.39) | KDM4EATML3MBTL1ALOX5MAPT | |
| SCHEMBL20175556 | 0.95 | L3MBTL1 (0.39) | KDM4EATML3MBTL1ALOX5MAPT | |
| SCHEMBL20175560 | 0.95 | L3MBTL1 (0.39) | KDM4EATML3MBTL1ALOX5MAPT | |
| SCHEMBL20175557 | 0.94 | KDM4E (0.37) | KDM4EATML3MBTL1ALOX5TSPO | |
| SCHEMBL19933770 | 0.94 | ATM (0.42) | KDM4EATML3MBTL1ALOX5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3266787-B1 | COMPOUND FOR ORGANIC ELECTRIC DEVICE, ORGANIC ELECTRIC DEVICE USING THE SAME, AND ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO LTD (KR) | 2022-07-06 | — | — | EP | disclosed |
| US-10717744-B2 | Compound for organic electric element, organic electric element comprising the same and electronic device thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2020-07-21 | — | — | US | disclosed |
| WO-2020085793-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING SAME, AND ELECTRONIC DEVICE COMPRISING SAME | 덕산네오룩스 주식회사 | 2020-04-30 | — | — | WO | disclosed |
| US-20180141957-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME AND ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
| US-20180141957-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME AND ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141957-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME AND ELECTRONIC DEVICE THEREOF | PIEZO1, OCIAD1, LEF1 | KDM4E 1121/4885ATM 4361/4885L3MBTL1 561/4885 |
| US-10717744-B2 | Compound for organic electric element, organic electric element comprising the same and electronic device thereof | PIEZO1, OCIAD1, LEF1 | KDM4E 1121/4885ATM 4361/4885L3MBTL1 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.